Potential role of rebamipide in osteoclast differentiation and mandibular condylar cartilage homeostasis

Takashi Izawa, Islamy Rahma Hutami, Eiji Tanaka

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative disease that involves changes in subchondral bone and progressive degradation of cartilage. Currently, rebamipide, a gastroprotective drug, is administered to protect gastric mucosa and accelerate ulcer healing. Objectives: Recent studies have shown that rebamipide also attenuates cartilage degeneration by suppressing oxidative damage and inducing homeostasis of the extracellular matrix of articular chondrocytes. Regarding the latter, reduced expression of cathepsin K, NFATc1, c-Src, and integrin β3, and increased expression of nuclear factor-kappa B, have been found to be mediated by the transcription factor, receptor activator of nuclear factor kappa-B ligand (RANKL). Methods: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation. Taken together, these results strongly indicate that rebamipide mediates inhibitory effects on cartilage degradation and osteoclastogenesis in TMJ-OA. Results and Conclusion: Here, we highlight recent evidence regarding the potential for rebamipide to affect osteoclast differentiation and TMJ-OA pathogenesis. We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.

Original languageEnglish
Pages (from-to)62-69
Number of pages8
JournalCurrent Rheumatology Reviews
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 1 2018
Externally publishedYes

Fingerprint

Osteoclasts
Cartilage
Homeostasis
Temporomandibular Joint
Osteoarthritis
Cathepsin K
RANK Ligand
NF-kappa B
Chondrocytes
Gastric Mucosa
Mitogen-Activated Protein Kinases
Osteogenesis
Integrins
Ulcer
Extracellular Matrix
rebamipide
Transcription Factors
Joints
Bone and Bones
Pharmaceutical Preparations

Keywords

  • Chondrocyte
  • Mitogen-activated
  • Osteoclast differentiation
  • Rebamipide
  • ROS
  • TMJ-OA

ASJC Scopus subject areas

  • Rheumatology

Cite this

Potential role of rebamipide in osteoclast differentiation and mandibular condylar cartilage homeostasis. / Izawa, Takashi; Hutami, Islamy Rahma; Tanaka, Eiji.

In: Current Rheumatology Reviews, Vol. 14, No. 1, 01.01.2018, p. 62-69.

Research output: Contribution to journalReview article

@article{d08bb8f9ca0d4f05bd4bc3241befb56b,
title = "Potential role of rebamipide in osteoclast differentiation and mandibular condylar cartilage homeostasis",
abstract = "Background: Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative disease that involves changes in subchondral bone and progressive degradation of cartilage. Currently, rebamipide, a gastroprotective drug, is administered to protect gastric mucosa and accelerate ulcer healing. Objectives: Recent studies have shown that rebamipide also attenuates cartilage degeneration by suppressing oxidative damage and inducing homeostasis of the extracellular matrix of articular chondrocytes. Regarding the latter, reduced expression of cathepsin K, NFATc1, c-Src, and integrin β3, and increased expression of nuclear factor-kappa B, have been found to be mediated by the transcription factor, receptor activator of nuclear factor kappa-B ligand (RANKL). Methods: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation. Taken together, these results strongly indicate that rebamipide mediates inhibitory effects on cartilage degradation and osteoclastogenesis in TMJ-OA. Results and Conclusion: Here, we highlight recent evidence regarding the potential for rebamipide to affect osteoclast differentiation and TMJ-OA pathogenesis. We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.",
keywords = "Chondrocyte, Mitogen-activated, Osteoclast differentiation, Rebamipide, ROS, TMJ-OA",
author = "Takashi Izawa and Hutami, {Islamy Rahma} and Eiji Tanaka",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1573397113666171017113441",
language = "English",
volume = "14",
pages = "62--69",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Potential role of rebamipide in osteoclast differentiation and mandibular condylar cartilage homeostasis

AU - Izawa, Takashi

AU - Hutami, Islamy Rahma

AU - Tanaka, Eiji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative disease that involves changes in subchondral bone and progressive degradation of cartilage. Currently, rebamipide, a gastroprotective drug, is administered to protect gastric mucosa and accelerate ulcer healing. Objectives: Recent studies have shown that rebamipide also attenuates cartilage degeneration by suppressing oxidative damage and inducing homeostasis of the extracellular matrix of articular chondrocytes. Regarding the latter, reduced expression of cathepsin K, NFATc1, c-Src, and integrin β3, and increased expression of nuclear factor-kappa B, have been found to be mediated by the transcription factor, receptor activator of nuclear factor kappa-B ligand (RANKL). Methods: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation. Taken together, these results strongly indicate that rebamipide mediates inhibitory effects on cartilage degradation and osteoclastogenesis in TMJ-OA. Results and Conclusion: Here, we highlight recent evidence regarding the potential for rebamipide to affect osteoclast differentiation and TMJ-OA pathogenesis. We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.

AB - Background: Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative disease that involves changes in subchondral bone and progressive degradation of cartilage. Currently, rebamipide, a gastroprotective drug, is administered to protect gastric mucosa and accelerate ulcer healing. Objectives: Recent studies have shown that rebamipide also attenuates cartilage degeneration by suppressing oxidative damage and inducing homeostasis of the extracellular matrix of articular chondrocytes. Regarding the latter, reduced expression of cathepsin K, NFATc1, c-Src, and integrin β3, and increased expression of nuclear factor-kappa B, have been found to be mediated by the transcription factor, receptor activator of nuclear factor kappa-B ligand (RANKL). Methods: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation. Taken together, these results strongly indicate that rebamipide mediates inhibitory effects on cartilage degradation and osteoclastogenesis in TMJ-OA. Results and Conclusion: Here, we highlight recent evidence regarding the potential for rebamipide to affect osteoclast differentiation and TMJ-OA pathogenesis. We also discuss the potential role of rebamipide to serve as a new strategy for the treatment of TMJ-OA.

KW - Chondrocyte

KW - Mitogen-activated

KW - Osteoclast differentiation

KW - Rebamipide

KW - ROS

KW - TMJ-OA

UR - http://www.scopus.com/inward/record.url?scp=85047724529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047724529&partnerID=8YFLogxK

U2 - 10.2174/1573397113666171017113441

DO - 10.2174/1573397113666171017113441

M3 - Review article

C2 - 29046162

AN - SCOPUS:85047724529

VL - 14

SP - 62

EP - 69

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 1

ER -